-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alpha-fetoprotein (AFP) is the most widely detected serum tumor marker for hepatocellular carcinoma (HCC), and AFP overexpression is thought to be a reflection of more aggressive tumor biology and burden
Atezolizuma+bevacizumab is the new standard of care for systemic-naïve, unresectable hepatocellular carcinoma (HCC)
The researchers used the data from the Phase Ib GO30140 study arm A to determine the optimal time to detect AFP and the cut-off value to distinguish different treatment responses in patients
A ≥75% decrease in AFP at 6 weeks of treatment was used as the cutoff to identify responders, and an AFP increase of ≤10% was used as the cutoff to identify patients with disease control Both AFP cutoffs were associated with longer overall survival and progression-free survival Both AFP cutoffs were associated with longer overall and progression-free survival
AFP response at week 6 of initiation of therapy as a surrogate biomarker of prognosis in patients with hepatocellular carcinoma receiving Atezolizuma + bevacizumab Surrogate biomarkers for prognosis in cancer patients
Original source:
Original source:Andrew X.
leave a message here